Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

First published in Diabetes, Obesity and Metabolism on 2014 May.
Diabetes Obes Metab. 2014 May;16(5):467-77. doi: 10.1111/dom.12273. Epub 2014 Mar 12.

Authors: Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.